Cannabinoids Elicit Antidepressant-Like Behavior And Activate Serotonergic Neurons

[Truth Seeker]

Abstract

Preclinical and clinical studies show that cannabis modulates mood and possesses antidepressant-like properties, mediated by the agonistic activity of cannabinoids on central CB1 receptors (CB1Rs). The action of CB1R agonists on the serotonin (5-HT) system, the major transmitter system involved in mood control and implicated in the mechanism of action of antidepressants, remains however poorly understood. In this study, we demonstrated that, at low doses, the CB1R agonist WIN55,212-2 [R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate] exerts potent antidepressant-like properties in the rat forced-swim test (FST). This effect is CB1R dependent because it was blocked by the CB1R antagonist rimonabant and is 5-HT mediated because it was abolished by pretreatment with the 5-HT-depleting agent parachlorophenylalanine. Then, using in vivo electrophysiology, we showed that low doses of WIN55,212-2 dose dependently enhanced dorsal raphe nucleus 5-HT neuronal activity through a CB1R-dependent mechanism. Conversely, high doses of WIN55,212-2 were ineffective in the FST and decreased 5-HT neuronal activity through a CB1R-independent mechanism. The CB1R agonist-induced enhancement of 5-HT neuronal activity was abolished by total or medial prefrontocortical, but not by lateral prefrontocortical, transection. Furthermore, 5-HT neuronal activity was enhanced by the local microinjection of WIN55,212-2 into the ventromedial prefrontal cortex (mPFCv) but not by the local microinjection of WIN55,212-2 into the lateral prefrontal cortex. Similarly, the microinjection of WIN55,212-2 into the mPFCv produced a CB1R-dependent antidepressant-like effect in the FST. These results demonstrate that CB1R agonists possess antidepressant-like properties and modulate 5-HT neuronal activity via the mPFCv.

Introduction

Cannabis is the most widely used illicit drug (World Health Organization, 2006). Its major psychoactive constituent, Δ9-tetrahydrocannabinol, and other cannabinoids exhibit high affinity to brain CB1 receptors (CB1Rs). CB1R activation modulates physiological, affective, cognitive, and psychomotor functions. Cannabis intoxication for instance engenders enhanced sociability, mood, and well-being, a condition described as "fatuous euphoria" (Iversen, 2003) whose physiological and subjective components are selectively blocked by the CB1R antagonist rimonabant (RIM) (Huestis et al., 2001).

Increased attention has been directed toward understanding the role of the endocannabinoid system in mood regulation. Clinical studies have reported benefits of cannabis on mood disorders (Ashton et al., 2005; Ware et al., 2005). Genetic (Haller et al., 2002, 2004; Martin et al., 2002) or pharmacological (Navarro et al., 1997; Deroche-Gamonet et al., 2001) CB1R blockade in murine models yields enhanced expression of depression/anxiety-like behaviors. There are conflicting reports on the mood-related effects of CB1R agonists and antagonists/inverse agonists with regards to direction and potency of effects. Shearman et al. (2003) for example reported instead an antidepressant-like activity of the CB1R inverse agonist AM251 [N-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide]. This apparent complexity has been attributed to dose-dependent bidirectional modulation, sensitivity of cannabimimetic responses to contextual conditions, and the kind of animal model and strain used (for review, see Viveros et al., 2005). Also, the possibility of interaction among receptor subtypes including a putative CB3R and vanilloid receptors, which has likewise been demonstrated operating in a plethora of cannabimimetic responses, may underlie ambivalent effects on mood modulation.

Despite evidence for the impact of CB1R activity on mood regulation, information on direct effects of cannabinoids on serotonergic neurotransmission remain meager. Serotonin (5-HT) is the major neurotransmitter implicated in mood pathophysiology and in the mechanism of antidepresssant action (Blier and de Montigny, 1999). Several studies have nevertheless provided indications of functional cannabinoid—5-HT interaction. First, the dorsal raphe (DR), the principal source of forebrain 5-HT, expresses the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) (Egertova et al., 1998, 2003), the CB1R in rats (Moldrich and Wenger, 2000), and CB1R mRNA in mice (Häring et al., 2007). Second, CB1Rs are abundantly expressed in the prefrontal cortex (PFC) (Marsicano and Lutz, 1999; Moldrich and Wenger, 2000), which sends excitatory afferents to the DR, coursing from the medial PFC (mPFC) (Jankowski and Sesack, 2004). Furthermore, upregulation in PFC CB1R density, likely a compensatory feedback, was observed in suicidal depressives (Hungund et al., 2004). Imaging studies revealed that cannabis alters PFC regional cerebral blood flow and metabolic activity. The degree was correlated with subjective effects, and the pattern was consistent with CB1R localization (Volkow et al., 1991; Matthew et al., 2002). Third, CB1R agonism alters 5-HT1A and 5HT2A receptor-mediated behavioral responses (Hill et al., 2006) and inhibits 5-HT reuptake in vitro (Banerjee et al., 1975; Johnson et al., 1976). In this study, we therefore aimed at determining whether the CB1R agonist WIN55,212-2 (WIN) [R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate] exhibits antidepressant-like effects in the forced swim test (FST), modulates 5-HT activity through a CB1R-mediated mechanism, and effects dose-dependent bidirectional modulations. Furthermore, using local microinfusions, we aimed to demonstrate that the mPFC is strongly involved in mediating these effects.

Materials and Methods

Animals
Adult male Sprague Dawley rats (Charles River, Saint-Constant, Quebec, Canada) weighing 280—350 g at the time of experiments were housed in pairs in standard polycarbonate cages. They were kept under standard laboratory conditions (12 h light/dark cycle, lights on at 7:30 A.M.; temperature at 20 ± 2°C; 50—60% relative humidity). All rats had ad libitum access to food and water. One week before the start of experiments, rats were exposed to the testing environment and allowed to habituate to testing conditions. For rats that have undergone intracerebral cannulation, weights were monitored after surgery, and at least 4 d of postoperative recovery period was observed before additional tests were conducted. Drug administrations and electrophysiological and behavioral experiments were conducted between 2:00 P.M. and 10:00 P.M. All procedures were approved by the local institutional animal care and use committee and were in accordance to the ethical guidelines set by the Canadian Institutes of Health Research and the Society for Neuroscience.

Drugs
The CB1R agonist WIN55,212-2 (Sigma, Oakville, Ontario, Canada) was emulsified in Tween 80 (polyoxyethylene-sorbitan mono-oleate; Sigma) and further dissolved in saline with 5% Tween 80 and 5% poly(ethylene) glycol (Sigma). The WIN55,212-2 solution used for intracerebral microinfusions was dissolved in dimethylsulfoxide (DMSO) (Sigma) and vehicle (VEH) (1:2) because of the hydrophobic property of WIN55—212-2. The CB1R antagonist SR141716A/rimonabant [N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-pyrazolecarboxamide] (a kind gift from Dr. D. Piomelli, University of California, Irvine, CA) and the transient receptor potential vanilloid type 1 (TRPV1)/vanilloid receptor antagonist capsazepine (CPZ) (Tocris Bioscience, Ballwin, MO) were initially dissolved in DMSO and further diluted (1:20) with saline containing 5% Tween 80 and 5% poly(ethylene) glycol. Desipramine hydrochloride (DMI), parachlorophenylalanine (pCPA) (Sigma), and citalopram hydrobromide (CIT) (kindly provided by Lundbeck, Copenhagen, Denmark), were dissolved in 0.9% physiological saline. The pH of vehicles and solutions used in the experiments was adjusted to 7.2.

Experiment 1: forced swim test
The FST examines the dynamics of transition from an active (swimming and climbing) to a passive (immobility) mode of coping in an inescapable cylindrical water pool (20 cm diameter, 50 cm high; 30 cm water depth, 25—27°C water temperature). During the course of the 5 min test swim session, an enhanced transition from activity to immobility resulting from a 15 min preexposure to the pool (preswim 24 h previously) has often been equated to learned behavioral despair (Porsolt et al., 1978). This enhancement of immobility is prevented by antidepressant treatment. Here, rats received 0.05, 0.2, 1.0, or 2.0 mg/kg intraperitoneal injections of the potent CB1R agonist WIN55,212-2 23, 5, and 0.75 h before the test swim, modified after the protocol previously described by Page et al. (1999). A second cohort of rats was used to assess the effect of coadministering rimonabant with the dose of WIN55,212-2 that elicited the maximal antidepressant-like effect. A third cohort of rats was used to verify the role of 5-HT in mediating the effects of WIN55,212-2. Vehicle or pCPA (350 mg/kg, i.p., once daily), a selective inhibitor of the 5-HT synthesis precursory enzyme tryptophan hydroxylase that therefore depletes endogenous 5-HT, was administered 72 and 48 h before the swim test. WIN55,212-2 (0.2 mg/kg, i.p.) or vehicle were administered 23, 5, and 0.75 h before the swim test (modified after Page et al., 1999). Behavioral endpoints were analyzed by an automated tracking system equipped with infrared-sensitive cameras (Videotrack; Viewpoint Life Science, Montreal, Quebec, Canada). The predominant behaviors assessed were subsumed to one of three categories: immobility, in which the rat was making minimal movements to keep its head above water; swimming, in which the rat was engaged in average movements that cause it to move (usually horizontally) within the cylinder; and climbing (burst activity), in which forceful thrashing limb movements against the walls of the cylinder were observed. It has been shown that antidepressants with 5-HT-specific action selectively increase the duration of swimming, whereas those with a predominantly noradrenergic-specific activity increase those of climbing (Page et al., 1999). In all sessions, each animal was held on the neck and back, gently immersed in the pool hindlimbs first. They were removed from the pool using a plastic grid, then dried with a towel, and caged near a heat source. The FST is both sensitive and selective for clinically effective antidepressants, has been repeatedly validated, and is currently the most popular model for detecting antidepressant activity attributable to its simplicity, reliability, and high predictive validity (Lucki, 1997; Cryan et al., 2005). To control for false positives (increased activity in the FST of non-antidepressants), as has been consistently observed with psychostimulants (for review, see Cryan et al., 2005), a test for locomotor activity (5 min) in an open field (80 × 80 cm), was also conducted, in which locomotor activity was operationalized as movement velocity (distance traveled in centimeters per minute).

Experiment 2: electrophysiology
In vivo extracellular single-unit recordings of presumed DR 5-HT neurons were performed to determine whether the antidepressant-like properties of WIN55,212-2 in the FST corresponded to a capacity to enhance 5-HT neurotransmission. Recordings were conducted after repeated intraperitoneal administration following the FST protocol as well as after intravenous administration. All stereotaxic coordinates used in the succeeding experiments were based on the stereotaxic atlas of Paxinos and Watson (1986).

Preparation for electrophysiological experiments.
Rats were anesthetized with chloral hydrate (400 mg/kg, i.p.) and mounted in a stereotaxic frame (David Kopf Instruments, Tujunga, CA) with the skull positioned horizontally (incisor bar at −3.3). To maintain a full anesthetic state characterized by the absence of a nociceptive reaction to a paw/tail pinch and eyeblink response to pressure, chloral hydrate was continuously administered intraperitoneally at a dose of 50—70 mg · kg−1 · h−1 using an infusion pump (Braintree Scientific, Braintree, MA). Body temperature was maintained at 37 ± 0.5°C throughout the experiment using a rectal probe and a heating pad (Seabrook International, Seabrook, NH). Before electrophysiological recordings, a catheter was inserted into the lateral tail vein to facilitate systemic administration of drugs. Extracellular single-unit recordings were performed using single-barreled glass micropipettes pulled from 2 mm Stoelting (Wood Dale, IL) capillary glass on a Narashige (Tokyo, Japan) PE-21 pipette puller and preloaded with fiberglass strands to promote capillary filling with 2% Pontamine Sky Blue dye in sodium acetate (0.5 M, pH 7.5). The micropipette tips were broken down to diameters of 1—3 μm. Electrode impedances ranged from 2 to 4 MΩ. At the end of each experiment, the recording site was marked by iontophoretic ejection (5—10 μA, negative current for 10 min) of Pontamine Sky Blue for histological verification.

Single-unit extracellular recordings of DR 5-HT neurons.
The dose—response of putative 5-HT neurons was assessed after single intravenous (0.05—0.8 mg/kg) and repeated intraperitoneal (0.05—2 mg/kg) administrations of WIN55,212-2. A burr hole was drilled on the midline, 1.2 mm anterior to interaural zero. Using a hydraulic micropositioner (model 650; David Kopf Instruments), the electrode was lowered into the DR. Putative 5-HT neurons were encountered immediately below the ventral border of the Sylvian aqueduct and abound between 5.0 and 6.5 mm ventral to the dura mater. These neurons under normal conditions were identified according to the following criteria: a slow (0.1—4 Hz) and prominently regular firing rate (coefficient of variation ranges from 0.12 to 0.87) and a broad positive action potential (0.8—3.5 ms; 1.4 ms first positive and negative deflections) (Baraban and Aghajanian, 1980; Allers and Sharp, 2003). An inhibitory response to the GABAB agonist baclofen after intravenous drug administrations also confirmed that neurons were 5-HT because GABAB receptors are almost exclusively limited to 5-HT neurons in the DR (Wirtshafter and Sheppard, 2001).

5-HT burst activity.
Burst activity pattern was analyzed based on the criteria of Gobbi et al. (2005), such that a train of at least two spikes with an onset defined by a maximum initial interspike interval of 20 ms within a regular low-frequency firing pattern was categorized as a burst. The longest interspike interval allowed within a burst was 40 ms. In intraperitoneal experiments, two to four electrode descents were made to obtain a maximal sample of neurons across the rostrocaudal medial extent of the DR presumed richest in 5-HT neurons (Descarries et al., 1982). Recordings were also performed after coadministration of rimonabant (1 mg/kg) injected intraperitoneally 10 min before the last WIN55,212-2 injection. Single-unit activity was recorded as discriminated action potentials amplified by a Tennelec (Oakridge, TN) TB3 MDA3 amplifier, postamplified and filtered by a Realistic 10 band frequency equalizer, digitalized by a CED1401 interface system (Cambridge Electronic Design, Cambridge, UK), processed on-line, and analyzed off-line by Spike2 software version 5.05 for Windows PC (Microsoft, Seattle, WA). Changes in neuronal firing pattern resulting from drug administrations were continuously monitored; the first 30 s immediately after drug injections were not considered to eliminate injection artifacts. Neurons were considered nonresponding if percentage change from baseline firing activity after drug administrations was <10%.

Experiment 3: PFC transections
To determine whether cannabinoid-induced modulation of DR 5-HT neurons originate in the PFC and are relayed via the descending corticoraphe fibers, systematic transections of the PFC—DR pathway were performed on anesthetized rats before electrophysiological recordings. For a total bilateral PFC transection (tPFC), a fine needle (0.35 mm diameter) was initially positioned at 1 mm anterior to bregma and 0.8 mm left of the midline. It was lowered 6.8 mm from the dura mater, slowly slid leftward 5 mm from the midline (0.5 mm/min), and then slowly retracted vertically using a micropositioner (10 μm/min). To avoid damaging the sinus, the needle was positioned 1.2 mm from the midline on the right hemisphere, lowered 6.8 mm at a 20° angle, and then moved 5 mm rightward (modified after Diaz-Mataix et al., 2005). Selective transection of PFC subregions were performed by positioning the needle 2.5 mm anterior to bregma, lowered 6.8 mm from the dura mater, and moved 1.5 mm (on both sides) from the midline for an mPFC transection (areas transected included the dorsal peduncular, infralimbic, prelimbic Cg3, and cingulate Cg1 cortices) or from 1.5 to 5 mm for a transection of the lateral aspect of the prefrontal cortex (latPFC): mainly the lateral prefrontal/agranular insular, but also the frontal Fr2, Fr1, and Fr3; the ventrolateral and lateral orbital cortices; and some parts of parietal area 1 (modified after Hajos et al., 1999). 5-HT single-unit recordings were conducted 1.5—2 h after transection.

Experiment 4: combined intracerebral microinfusion and electrophysiology
Experiment 4A: intracerebral microinfusion into the dorsal raphe nucleus.
Anesthetized rats were implanted with a single guide cannula (22 gauge; Plastics One, Roanoke, VA) for intra-DR microinfusion of WIN55,212-2. The guide cannula was angled at 25° from the vertical axis and aimed 1 mm above the DR to allow termination of the injector tip within the nucleus (+1.2 mm from interaural zero, ±1.4 from midline, and −6.0 mm from the dura mater). The cannula was fixed to the skull with the use of skull screws and dental acrylic. A 1.5—2 h postoperative interim period was allowed before the start of electrophysiological recordings (as described above in experiment 2). Once a stably firing 5-HT neuron was found and 1—3 min of baseline activity was established, microinfusion of either vehicle (0.5 μl) or WIN55,212-2 (5 μg/0.5 μl) was initiated and continuously delivered for 3 min. Substances were infused into the DR via a 28 gauge stainless steel injector attached by polyethylene tubing to a 1 ml syringe driven by a CMA 400 microdialysis syringe pump (CMA Microdialysis, Solma, Sweden). Changes in neuronal discharge pattern were continually monitored for up to 45 min after the cessation of microinfusion. The probability that results were confounded by random diffusion of solutions to neighboring structures was remote because, aside from the strictly controlled injection volume, the vehicle used was relatively viscous and lipophilic compared with conventional solvents. To mark the site of injection at the end of each experiment, a small volume (50 nl/cannula) of Pontamine Sky Blue was infused via the same injector that was used for drug injections or was iontophoretically ejected from the recording pipette (see Fig. 5C).

Experiment 4B: intracerebral microinfusion into the prefrontal cortex, intra-mPFCv.
Simultaneous bilateral microinfusion of WIN55,212-2 (5 μg/0.5 μl) into the ventromedial subregions of the mPFC (mPFCv) (prelimbic—infralimbic cortices; +2.2 mm from bregma, ±0.5 from midline, −3.5 mm from the dura mater) was performed using a bilateral guide cannula (22 gauge, 1 mm center-to-center distance; Plastics One). The rest of the procedure was as described in the intra-DR microinfusion experiment (see above, experiment 4A).

Experiment 4C: intracerebral microinfusion into the prefrontal cortex, intra-latPFC.
Simultaneous bilateral microinfusion of WIN55,212-2 (5 μg/0.5 μl) into the latPFC (agranular insular cortex; +3.2 mm from bregma, ±4.2 from midline, and −4.2 mm from the dura mater) was performed with two single guide cannulas (22 gauge; Plastics One). The rest of the procedure was as described in the intra-DR microinfusion experiment (see above, experiment 4A).

Experiment 4D: intracerebral microinfusion into the prefrontal cortex, intra-mPFCv with PFC transection.
To confirm whether the integrity of the mPFC—DR pathway is required for the modulatory effect of WIN55,212-2 on DR 5-HT neurons, a final negative control procedure was performed by combined microinfusion and electrophysiological techniques on PFC-transected rats. Anesthetized rats first underwent transection of the PFC (1 mm anterior to bregma; see above, experiment 3) and immediately implanted with a bilateral cannula into the mPFCv, as described previously (2.2 mm anterior to bregma; see above, experiment 4B) anterior to the transection lesion. Then, following the procedure used in experiment 4B, WIN55,212-2 was infused while performing single-unit recording on a DR 5-HT neuron.

Experiment 5: intracerebral mPFCv microinfusion and FST
Under Equithesin anesthesia (3 ml/kg) (1.96 g of sodium pentobarbital, 8.5 g of chloral hydrate, 4.25 g of MgSO4 hexahydrate, 60 ml of propylene glycol, 20 ml of ethanol, and 58 ml of distilled water, adjusted to 200 ml with distilled water), rats were mounted in a stereotaxic frame as described previously. Cannulation procedure was the same as in experiment 4B. After surgery, the incisions were stitched and applied with antiseptics. The cannulas were occluded with stainless steel wire stylets (Plastics One) to maintain patency. A postoperative recovery period of 8 d was allowed. Thereafter, cannulated rats were submitted to the FST (see above, experiment 1). A 15 min preswim test was conducted. The next day, rats were allowed to habituate to the testing room for 2 h before microinfusion. Then, WIN55,212-2 (1 or 5 μg in 0.5 μl of vehicle) or vehicle (0.5 μl) was continuously delivered for 3 min. In some cases, infusion of rimonabant [1 μg (Caillé and Parsons, 2006) in 0.25 μl of vehicle for 1.5 min] was performed 1 min before infusion of WIN55,212-2 (1 μg in 0.25 μl of vehicle for 1.5 min). In all groups, total infusion volume was 0.5 μl. The microinfusion connector assembly was left in place 4 more min to allow the drug solution to diffuse into the target structure (mPFCv). The rats were then placed in the cylindrical pool and subjected to the FST (5 min test swim recording).

Histology
Histological verification of the extent and selectivity of lesions imprinted by transections and cannula/microinjector trajectories were performed at the end of each experiment. The rats were deeply anesthetized (400 mg/kg chloral hydrate, i.p.) and then perfused according to standard procedures (fixative, 4% paraformaldehyde with 0.1% glutaraldehyde). The brains were harvested and postfixed in 4% paraformaldehyde overnight and incubated in 30% sucrose for 2 d. Adjacent series of 20—50 μA brain slices within the vicinity of lesions were cut using a freezing microtome and stained with thionin acetate (Sigma) for light microscopic verification or stored in a cryoprotectant solution at −20% until inspection.

Statistical analyses
SPSS (version 13; SPSS, Chicago, IL) was used to organize and statistically analyze data. All data were expressed as mean ± SEM and were submitted to parametric tests (one-way or two-way ANOVA), followed by Student's t test/Dunnett's test for post hoc comparisons. When assumptions of normality and variance homogeneity were not satisfied, nonparametric tests (Kruskal—Wallis or Friedman's tests for ANOVA, Mann—Whitney U test for post hoc comparisons) were performed. Dunnett's post hoc test was used for comparing with baseline drug-induced changes in neuronal activity. Nonlinear curve fitting and the calculation of ED50 were performed using Microcal Software (Northampton, MA) Origin (version 7). Fisher's exact test was used to assess the differential response to CB1R blockade versus TRPV1 blockade after intravenous administrations of rimonabant and capsazepine. Statistical values reaching p ≤ 0.05 were considered significant.

Results

Effect of subchronic low and high doses of WIN55,212-2 in the FST
To examine the possible dose-dependent effect of CB1R agonists on stress-coping behavior, we tested low and high doses of WIN55,212-2 in the FST. A low dose of WIN55,212-2 (0.2 mg/kg, i.p.) compared with vehicle elicited a significant decrease in total time spent in immobility (WIN at 0.2 mg/kg, 54.05 ± 11.11; VEH, 159.9 ± 10.94; −66.2%, p < 0.01) (Fig. 1A) and a significant increase in total swimming duration (WIN at 0.2 mg/kg, 220.08 ± 10.39; VEH, 128.86 ± 10.72; +70.79%, p < 0.01) (Fig. 1A) but did not affect total climbing duration [WIN at 0.2 mg/kg, 24.73 ± 4.79; VEH, 11.21 ± 15; no significant difference (NS)] (Fig. 1A). These effects were comparable with those produced by the clinically used selective serotonin reuptake inhibitor (SSRI) antidepressant citalopram (5 mg/kg, i.p.; immobility, 47.8 ± 15.25, −72.84%, p < 0.01 vs VEH; swimming, 218.83 ± 25.4, +119.8%, p < 0.01 vs VEH; climbing, 33.33 ± 13.78, +36.37%, NS vs VEH) (Fig. 1A). Conversely, the selective norepinephrine reuptake inhibitor DMI (10 mg/kg, i.p.) elicited a decrease in total immobility duration (30 ± 6.57, −82.95%, p < 0.01 vs VEH) and an increase in total climbing duration (142.01 ± 19.6, +481.06%, p < 0.01 vs VEH) but not an increase in total swimming duration (127.99 ± 14.88, +28.56%, NS vs VEH), confirming its primary action on noradrenergic transmission (Fig. 1A). The effects of the low dose of WIN55,212-2 on immobility and swimming behaviors were prevented by the coadministration of the CB1R antagonist RIM (1 mg/kg, i.p.) (WIN at 0.2 mg/kg plus RIM at 1 mg/kg, i.p.; immobility, 122.52 ± 26.49, −23.38%, NS vs VEH; swimming, 154.16 ± 25.39, +19.63%, NS vs VEH) (Fig. 1A). A high dose of WIN55,212-2 (2 mg/kg, i.p.) did not shorten total immobility duration (174.91 ± 36.57, −0.91%, NS vs VEH) and prolonged neither total swim duration (106.42 ± 32.1, +6.89%, NS vs VEH) nor total climbing duration (17.16 ± 6.5, −29.79%, NS vs VEH) (Fig. 1A). This inert activity of the high dose of WIN55,212-2 was not changed during coapplication with RIM (WIN at 2.0 mg/kg plus RIM at 1 mg/kg, i.p; immobility, 122.52 ± 26.49; swimming, 154.16 ± 25.39; or climbing, 23.4 ± 2.0 vs VEH, NS) (Fig. 1A). RIM (1 mg/kg, i.p.) did not induce any significant change in behavior (immobility, 128.32 ± 23.26; swimming, 159.34 ± 22.48; or climbing, 12.46 ± 2.0 vs VEH, NS) (Fig. 1A). The locomotor activity (movement velocity) of all drug-treated groups were not significantly different from that of the vehicle-treated group (CIT at 5 mg/kg, 433.24 ± 19.52; DMI at 10 mg/kg, 423.97 ± 22.44; WIN at 0.05 mg/kg, 423.21 ± 30.12; WIN at 0.10 mg/kg, 445.65 ± 29.45; WIN at 0.2 mg/kg, 434.71 ± 26.31; WIN at 2.0 mg/kg, 371.26 ± 33.16; WIN at 0.2 mg/kg plus RIM at 1 mg/kg, 476.82 ± 21.46; WIN at 2.0 mg/kg plus RIM at 1 mg/kg, 382.12 ± 37.26; or RIM at 1 mg/kg, 399.92 ± 22.50, NS vs VEH, 433.23 ± 24.21).

Effect of pCPA pretreatment on WIN55,212-2 antidepressant-like activity in the FST
Because the activity of the low dose of WIN55,212-2 in the FST was similar to that of the SSRI citalopram, we tested whether this antidepressant-like activity was via a main action on 5-HT transmission as observed with SSRIs (Page et al., 1999). When injected with the low dose of WIN55,212-2, rats pretreated with the 5-HT-depleting agent pCPA expressed neither increased swimming behavior (pCPA plus WIN at 0.2 mg/kg, i.p., 166.35 ± 15.06 vs VEH plus VEH, 142.54 ± 17.2, NS) (Fig. 1B) nor decreased immobility (pCPA plus WIN at 0.2 mg/kg, i.p., 112.54 ± 15.35 vs VEH plus VEH, 134.34 ± 18.3, NS) (Fig. 1B). Pretreatment of pCPA alone did not induce any effect significantly different from vehicle pretreatment (pCPA plus VEH; immobility, 118.57 ± 9.72; swimming, 160.6 ± 9.65; or climbing, 20.93 ± 2.24 vs VEH plus VEH, NS) (Fig. 1B).

Effect of subchronic intraperitoneal doses of WIN55,212-2 on 5-HT single-unit activity
To test whether antidepressant-like behavioral effects of WIN55,212-2 in the FST were paralleled by enhanced 5-HT neuronal firing activity, we performed in vivo extracellular recordings of presumed 5-HT neurons following the same treatment schedule as in the FST. WIN55,212-2 was administered 23, 5, and 0.75 h before electrophysiological recordings. In some animals, RIM was injected intraperitoneally 10 min before the third administration of 0.2 mg/kg WIN55,212-2. Mean spontaneous firing rate of 5-HT neurons showed a biphasic response profile after incremental doses of WIN55,212-2. One-way ANOVA revealed a dose-dependent increase with lower doses of WIN55,212-2 (VEH, 1.14 ± 0.04; WIN at 0.05 mg/kg, 1.35 ± 0.11; WIN at 0.1 mg/kg, 1.88 ± 0.15; WIN at 0.2 mg/kg, 2.58 ± 0.25; F(3,203) = 10.97; p < 0.01) (Fig. 2A), and the coadministration of RIM prevented this increase. A dose of 0.2 mg/kg WIN55,212-2 yielded a maximal 126.32% increase in neuronal activity. Conversely, a high dose of WIN55,212-2 (2.0 mg/kg) yielded a significant decrease compared with vehicle (WIN at 2.0 mg/kg, 0.41 ± 0.11, −64%, p < 0.01 vs VEH) (Fig. 2A). We also calculated the mean number of neurons per electrode descent, which served as an indirect measure of spontaneously active neurons (Gobbi et al., 2007). Compared with vehicle injections (VEH, 3.75 ± 0.16), there were 28% more spontaneously active 5-HT neurons after treatment with 0.1 mg/kg WIN55,212-2 (4.8 ± 0.39, p < 0.05) and 33.33% more active neurons with 0.2 mg/kg WIN55,212-2 (5.0 ± 0.46, p < 0.01), whereas a high dose of WIN55,212-2 had fewer active neurons than the control (WIN at 2.0 mg/kg, 1.92 ± 0.39, −48.8%, p < 0.01). The number of spontaneously active neurons in rats treated with a low dose of WIN55,212-2 (0.2 mg/kg) coapplied with RIM (1.0 mg/kg) did not significantly differ from those treated with the vehicle (Fig. 2B).

Effects of a single intravenous administration of low doses of WIN55,212-2 on 5-HT firing activity
To appraise whether the CB1R agonist WIN55,212-2 rapidly influences 5-HT neurotransmission, we measured the spontaneous single-unit firing activity of DR 5-HT neurons after cumulative intravenous administration of WIN55,212-2. Incremental doses of WIN55,212-2 (0.05—0.2 mg/kg) evoked a dose-dependent increase in 5-HT unit firing activity (F(3,62) = 4.64, p < 0.01, one-way ANOVA; VEH, 1.04 ± 0.10 Hz; WIN at 0.05 mg/kg, 1.17 ± 0.28 Hz; WIN at 0.1 mg/kg, 1.61 ± 0.37; WIN at 0.2 mg/kg, 2.04 ± 0.27) (Fig. 3E), which was half-maximal (ED50) at a dose of 0.1 mg/kg and was not blocked by capsazepine (20 μg/kg, i.v.) but was blocked by RIM (1 mg/kg, i.v.) in 100% of neurons tested (n = 4; Fisher's test, p = 0.01) (Fig. 3A). WIN55,212-2 treatment also increased burst activity, a pattern of neural activity that is associated with enhanced 5-HT release in postsynaptic regions (Gartside et al., 2000), as well as antidepressant-like activity (Gobbi et al., 2005). The maximal increase in burst frequency from baseline (percentage recorded spikes contained in bursts) was recorded at 0.2 mg/kg (VEH, 3.71 ± 1.16%; WIN at 0.05 mg/kg, 8.85 ± 3.59%; WIN at 0.1 mg/kg, 9.61 ± 3.15%; WIN at 0.2 mg/kg, 12.51 ± 4.07; χ2(3) = 12.56; p < 0.01, Kruskal—Wallis test) (Fig. 3F, top). The maximal increase in the mean number of spikes in a burst was 324% occurring at 0.2 mg/kg (VEH, 0.63 ± 0.13; WIN at 0.05 mg/kg, 1.23 ± 0.42; WIN at 0.1 mg/kg, 1.28 ± 0.32; WIN at 0.2 mg/kg, 2.67 ± 1.3; χ2(3) = 10.01; p < 0.01, Kruskal—Wallis test) (data not shown). Mean burst length was 82.25, 235.35, and 175.83% greater than baseline (vehicle) after incremental doses of 0.05, 0.1, and 0.2 mg/kg WIN55,212-2, respectively (VEH, 13.24 ± 3.75 ms; WIN at 0.05 mg/kg, 24.13 ± 10.79 ms; WIN at 0.1 mg/kg, 44.4 ± 18.1 ms; WIN at 0.2 mg/kg, 36.52 ± 14.64 ms; χ2(3) = 9.03; p < 0.05, Kruskal—Wallis test) (Fig. 3F, bottom). Among all neurons recorded, 66.67% (n = 16) of 5-HT neurons responded to increasing dose injections of WIN55,212-2, whereas 33.33% (n = 8) of neurons were nonresponding. All responding and nonresponding neurons showed the same electrophysiological characteristics, were inhibited by baclofen, and were localized in the DR.

Effects of a single intravenous administration of high doses of WIN55,212-2 on 5-HT firing activity
Remarkably, cumulative doses higher than 0.2 mg/kg WIN55,212-2 injected intravenously generally produced a decline in neuronal excitation significant at both 0.3 and 0.4 mg/kg and achieved a maximal level 45% below baseline (vehicle) after 0.4 mg/kg WIN55,212-2 (VEH, 1.04 ± 0.10 Hz; WIN at 0.04 mg/kg, 0.59 ± 0.08 Hz; F(1,45) = 6.7; p < 0.01) (Fig. 3E). A waning of stimulatory effects was also observed with burst activity: burst frequency (percentage of total number of recorded spikes; WIN at 0.3 mg/kg, 3.9 ± 2.85%; WIN at 0.4 mg/kg, 2.67 ± 1.82; WIN at 0.5 mg/kg, 10.51 ± 6.21%) (Fig. 3F, top), mean number of spikes in a burst (WIN at 0.3 mg/kg, 0.64 ± 0.34; WIN at 0.4 mg/kg, 1.83 ± 1.11; WIN at 0.5 mg/kg, 1.5 ± 0.5) (data not shown), mean burst length (WIN at 0.3 mg/kg, 20.73 ± 15.94 ms; WIN at 0.4 mg/kg, 19.54 ± 9.59 ms; WIN at 0.5 mg/kg, 15.53 ± 7.75 ms) (Fig. 3F, bottom). The CB1R antagonist RIM (1 mg/kg, i.v.) partially reversed this decline only in one of four neurons (Fig. 3B). Three neurons were nonresponsive (Fig. 3C). In two of three neurons tested, capsazepine reversed the decrease induced by high doses of WIN55,212-2 (Fig. 3D). This complex response pattern suggests that the CB1R may not be involved in the 5-HT effects induced by high doses of WIN55,212-2 (Fisher's test, p = 0.57, NS). Neither RIM (RIM at 1 mg/kg, i.v.) alone nor capsazepine (CPZ at 20 μg/kg, i.v.) alone had a significant effect on 5-HT single-unit firing activity (VEH, 1.3 ± 0.33; CPZ, 1.2 ± 0.57, n = 5; RIM, 1.48 ± 0.52, n = 7).

5-HT single-unit activity after PFC transections
DR 5-HT neurons receive important excitatory inputs from pyramidal (glutamatergic) cells of the PFC (Jankowski and Sesack, 2004). To verify whether cortical CB1Rs in the PFC or its subregions are essential in the control of DR 5-HT neurons by cannabinoids, rats were subjected to a tPFC, latPFC, or mPFC deafferentation by mechanical transection before 5-HT single-unit recordings. After tPFC transection, we observed that WIN55,212-2 failed to increase 5-HT single-unit firing activity at otherwise stimulatory doses in intact brains (tPFC transection: baseline, 1.46 ± 0.39 Hz, n = 7; WIN at 0.05 mg/kg, 0.78 ± 0.17 Hz, n = 6; WIN at 0.1 mg/kg, 0.91 ± 0.25 Hz, n = 5; WIN at 0.2 mg/kg, 0.97 ± 0.29 Hz, n = 5; WIN at 0.3 mg/kg, 1.04 ± 0.18 Hz, n = 4; WIN at 0.4 mg/kg, 0.97 ± 0.17 Hz, n = 4; WIN at 0.5 mg/kg, 1.10 ± 0.15 Hz, n = 4; WIN at 0.6 mg/kg, 1.31 ± 0.40 Hz, n = 3; p < 0.01) (Fig. 4A). We noted that, at doses higher than 0.6 mg/kg intravenously, a moderate increase of firing activity can be elicited but was not sensitive to RIM (non-CB1R-selective), which may indicate unspecific binding (data not shown). To pinpoint the specific subregion of the PFC that is critical in mediating the modulation of 5-HT single-unit activity, we compared transection of the mPFC with that of the latPFC. The response of 5-HT single units to the latPFC did not significantly differ from the control (baseline, 1.40 ± 0.12 Hz, n = 4; WIN at 0.05 mg/kg, 1.97 ± 0.57 Hz, n = 4; WIN at 0.1 mg/kg, 2.18 ± 0.59 Hz, n = 4; WIN at 0.2 mg/kg, 0.96 ± 0.02 Hz, n = 4; NS vs control, between-groups ANOVA) (Fig. 4A). On the contrary, mPFC transection produced an effect similar to tPFC transection and was significantly different from the control (baseline, 0.79 ± 0.22 Hz, n = 4; WIN at 0.05 mg/kg, 0.79 ± 0.20 Hz, n = 4; WIN at 0.1 mg/kg, 0.81 ± 0.23 Hz, n = 4; WIN at 0.2 mg/kg, 0.69 ± 0.26 Hz, n = 4; WIN at 0.3 mg/kg, −0.62 ± 0.30 Hz, n = 4; WIN at 0.4 mg/kg, 0.71 ± 0.21 Hz, n = 4; WIN at 0.6 mg/kg, 1.03 ± 0.33 Hz, n = 4; WIN at 0.7 mg/kg, 0.87 ± 0.06, n = 4; p < 0.05 vs control, between-groups ANOVA) (Fig. 4A), thus indicating that the medial, but not lateral, parts are responsible for the 5-HT firing activity enhancement by CB1R agonism. The transection procedure did not significantly modify the basal discharge rate of DR 5-HT neurons as was also observed by Hajos et al. (1999).

Microinfusion of WIN55,212-2 into the mPFCv and DR: electrophysiology on 5-HT neurons
To further localize the action of cannabinoids on 5-HT neurons, local microinfusion experiments were performed. Because the CB1R (Moldrich and Wenger, 2000) and CB1R mRNA (Häring et al., 2007) are present in the DR, it appeared reasonable to begin our attempt to localize the action of WIN55,212-2 within this nucleus, with the hypothesis that cannabinoid-induced 5-HT neuronal modulation occurs through local DR circuits. The microinfusion of WIN55,212-2 into the DR elicited a rapid increase (63.64%) and decrease (30%) in single-unit firing activity in one positive responder and one negative responder, respectively. The other two of four neurons recorded were nonresponders (Fig. 5A,B).

The mPFCv is functionally associated with stress and coping mechanisms through the regulation of the DR (Amat et al., 2005). Therefore, we further assessed the impact of CB1R activation in the ventral prelimbic—infralimbic cortex (mPFCv) on 5-HT single-unit activity. To strengthen results obtained from the selective mPFC transection, we locally microinfused WIN55,212-2 into the mPFCv of both cortical hemispheres. Corroborating the results from the transections (experiment 3), a gradual increase in 5-HT single-unit firing activity was elicited in four of five (80%) neurons recorded. This increase plateaued after 10—20 min and was rapidly nullified by the injection of RIM (1 mg/kg, i.v.) (Fig. 6A). Furthermore, microinfusion of WIN55,212-2 into the same site in mPFC-transected brains (n = 2) (Fig. 6C) as well as into the latPFC (n = 2) (Fig. 6D) did not elicit an increase in 5-HT single-unit activity in support of the necessity of the mPFC in cannabinoid-induced modulation of DR 5-HT neurons.

Microinfusion of WIN55,212-2 into the mPFCv: behavior in the FST
Because the results obtained from intracerebral WIN55,212-2 microinfusions with electrophysiology seemed to point to the mPFCv as a structure that plays an important role in cannabinoid-induced activation of DR 5-HT neurons, we therefore examined whether local bilateral microinfusion of WIN55,212-2 into the mPFCv is sufficient to alter stress-coping behaviors in the FST. Both microdoses of WIN55,212-2 used (1 and 5 μg in 0.5 μl of vehicle), compared with vehicle, produced a reduction of 47.43 and 36.24%, respectively, in total immobility time (VEH, 142.92 ± 14.29 s; WIN at 1 μg, 75.13 ± 15.74 s; WIN at 5 μg, 90.12 ± 20.93 s; p < 0.01 vs VEH) (Fig. 7) and an enhancement of 38.78 and 32.31%, respectively, in total swimming time (VEH, 141.09 ± 12.97 s; WIN at 1 μg, 195.81 ± 15.49 s; WIN at 5 μg, 186.68 ± 18.84 s; p < 0.01 vs VEH) (Fig. 7). There were no significant changes observed in climbing behavior (VEH, 16.07 ± 3.23 s; WIN at 1 μg, 29.2 ± 5.22 s; WIN at 5 μg, 21.50 ± 7.43 s; NS vs VEH) (Fig. 7), implying that enhancement in noradrenergic transmission may not be as important as enhancement in serotonergic transmission in mediating the antidepressant-like effects of WIN55,212-2 in the FST. A microdose of RIM (1 μg) that by itself did not induce any significant effect in the FST (immobility, 05.0 ± 40; swimming, 170.5 ± 20.2; or climbing, 23.5 ± 10 vs VEH, NS) blocked the effect of 1 μg of WIN55,212-2 when microinfused 1 min before WIN55,212-2. In the open-field test, neither WIN55,212-2, RIM, nor RIM plus WIN55,212-2 induced a change in locomotor activity with the microdoses used, eliminating the possibility of a false positive in the FST (VEH, 422.93 ± 41.38; WIN at 1 μg, 400.31 ± 50.86; WIN at 5 μg, 397.89 ± 64.02; RIM at 1 μg plus WIN at 1 μg, 431.43 ± 42.12; or RIM at 1 μg, 455.26 ± 31.9).

Discussion

These results establish that low doses of a CB1R agonist elicit potent antidepressant-like behavior and enhance 5-HT neurotransmission, mediated by CB1R activation in the mPFCv. Conversely, high doses nullify antidepressant-like behavior and markedly attenuate 5-HT neurotransmission, an effect that appears to be instigated by a non-CB1R mechanism.

Similar to antidepressants selectively blocking 5-HT reuptake (SSRIs), the CB1R agonist WIN55,212-2 potently decreased immobility and increased swim behavior in the FST. This was attributed to direct CB1R activation that modulates 5-HT because it was blocked by the CB1R antagonist rimonabant and the 5-HT-depleting agent pCPA. Highlighting the role of CB1R in mood regulation, preclinical studies have indeed shown that its genetic and pharmacological blockade rendered animals more emotionally reactive and anxious (Haller et al., 2002, 2004; Martin et al., 2002), susceptible to chronic stress-induced anhedonia (Martin et al., 2002), and liable to impairments in hypothalamic—pituitary—adrenal regulation (Barna et al., 2004) reminiscent of neuroendocrine dysfunction observed in depression. Interestingly, CB1R knock-out mice presented impaired extinction of aversive memories (Marsicano et al., 2002), invoking the pathological hallmark of posttraumatic stress disorder, a condition possessing overlapping symptomatology and high rate of comorbidity with major depression (Vieweg et al., 2006). Antidepressant-like effects in the FST have also been reported previously with the endocannabinoid reuptake inhibitor AM404 [N-(4-hydroxyphenyl)-arachidonamide] (Hill and Gorzalka, 2005) and the direct CB1R agonist HU-210 [3-(1,1-dimethylheptyl)-(−)-11-hydroxy-Δ8-tetrahydro-cannabinol] (Hill and Gorzalka, 2005; Jiang et al., 2005). Chronic HU-210 treatment was also found to drive hippocampal cell proliferation (Jiang et al., 2005), believed to be a downstream sequela of antidepressant treatment (Malberg et al., 2000). We recently demonstrated that the selective FAAH inhibitor URB597 cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3yl ester possesses antidepressant-like properties in the FST, tail suspension test (Gobbi et al., 2005), and chronic mild stress paradigm (Bortolato et al., 2007), in support of the concept that the endocannabinoid system may serve as target for depression therapy without the unwanted psychotropic effects of direct CB1R agonists. Moreover, perturbations in endocannabinoid signaling may very well be implicated in depression etiology, supported by the following. First, chronic unpredictable stress, used to model anhedonia, a core depression symptom, is associated with decreased endocannabinoid 2-arachidonoylglycerol in the rat hippocampus (Hill et al., 2005). Second, in humans, upregulation of PFC CB1R in suicidal depressives may indicate an adaptive response to decreased endocannabinoids (Hungund et al., 2004). Third, randomized trials of the CB1R antagonist rimonabant for obesity management increased adverse effects of depression and anxiety (Bronander and Bloch, 2007).

We demonstrated that WIN55,212-2 dose dependently enhances the number, firing, and burst activity of spontaneously active DR 5-HT neurons, corroborating microdialysis experiments that found increased synaptic 5-HT release in subcortical target regions (Fadda et al., 2006). We reported that elevating intrinsic anandamide through URB597 similarly elicited increased 5-HT activity (Gobbi et al., 2005). Both URB597 and WIN55,212-2 effects were CB1R mediated because these were blocked by rimonabant. Noteworthy, the effects here observed with WIN55,212-2 were markedly different from those exerted by URB597 in at least two features. First, WIN55,212-2 elicited a rapid response as opposed to the 2 h delay with URB597; this difference might be ascribed to the kinetics of FAAH inhibition preceding anandamide-induced CB1R activation. Second, higher URB597 doses produced an enduring (plateau effect) excitation (Gobbi et al., 2005), whereas higher doses of WIN55,212-2 resulted in a rapid decline in excitation; this difference could be attributable to the fact that direct CB1R agonists activate whole-brain CB1Rs, whereas FAAH inhibitors indirectly activate a subpopulation of these receptors colocalized with FAAH.

We identified that a CB1R subpopulation mediating 5-HT excitatory response to WIN55,212-2 is localized in the mPFC, the main source of cortical afferents to the DR (Hajos et al., 1999; Jankowski and Sesack, 2004). Convergent with results shown here, limbic 5-HT was enhanced after electrical stimulation of the mPFC but not of the latPFC (Juckel et al., 1999). Indeed, transecting mPFC efferents to the DR abolished the response of all recorded DR 5-HT neurons to the excitatory dose of WIN55,212-2. This was not observed after latPFC transection because of the absence of DR afferents from this area (Peyron et al., 1998). We surmise that the mPFCv particularly contained this receptor subpopulation because WIN55,212-2 bilaterally infused into this subregion markedly decreased FST immobility and increased basal discharge activity of DR 5-HT neurons. These effects were blocked by rimonabant.

The action of WIN55,212-2 may be explained by an enhanced feedforward excitatory input along mPFC—DR monosynaptic projections to 5-HT neurons possibly driven by disinhibiting pyramidal neurons (Fortin et al., 2004). Disinhibition was likely engaged by CB1R inhibitory control of cortical interneurons (Trettel and Levine, 2002), in agreement with the Gi/o-protein-linked transduction mechanism known to be associated with it and the resultant inhibition of voltage-sensitive calcium channels (Piomelli, 2003). This view is strengthened by the abundant perisomatic expression of CB1Rs in neocortical and PFC interneurons (Tsou et al., 1998; Marsicano and Lutz, 1999). Also, cannabinoids have been shown to increase cortical excitatory transmission and net spiking probability of pyramidal neurons in vivo (Pistis et al., 2001; Fortin et al., 2004), consistent with a concurrent increment of basal glutamate levels and decrement of basal GABA levels in prefrontocortical microdialysis experiments observed in anesthetized (Pistis et al., 2002) and awake (Ferraro et al., 2001) rats, as well as in prefrontocortical in vitro culture (Ferraro et al., 2001; Tomasini et al., 2002).

The degree of controllability over stressors is processed by the mPFCv, which in turn influences brainstem monoaminergic activity, particularly the DR (Amat et al., 2005, 2006; Maier et al., 2006). As such, it can be posited that the integrity of DR function in normosensitive states in relation to stress-coping and mood-related behaviors relies on the efficiency of mPFCv pyramidal activity. The therapeutic relevance of increasing pyramidal transmission becomes explicit on consideration that simply brief exposures to uncontrollable stress already can inflict significant dendritic retraction of infralimbic pyramidal neurons and impair stress-coping and fear extinction in murines (Izquierdo et al., 2006). Incidentally, hyperactivating anandamide through FAAH knock-out, thereby enhancing intrinsic CB1R activity, has been observed to modulate PFC plasticity, significantly increasing dendritic spine density (Patel et al., 2007). This neuroplastic change is as well akin to an antidepressant-like effect on the mPFC observed after chronic antidepressant treatment (Sairanen et al., 2007).

Finally, we presented evidence that increasing WIN55,212-2 dose produces a bidirectional profile in the modulation of 5-HT neuronal firing and burst activity, as well as in FST antidepressant-like behavior. This effect mirrors classical biphasic/bidirectional biochemical, physiological, and psychopharmacological modulations by cannabinoids reported previously (for review, see Chaperon and Thiebot, 1999). Moreover, this bidirectional effect may explain the succession of euphoria and dysphoria during cannabis intoxication (American Psychiatric Association, 1994; Iversen, 2003), a phenomenon validated by neuropsychological measures (Ashton et al., 1981).

Although we point to mPFCv CB1R as instrumental to WIN55,212-2-induced antidepressant-like effect and 5-HT activity enhancement, the 5-HT-decreasing effect appeared to be independent of CB1R. The inert effect of high WIN55,212-2 doses in the FST and the decline in 5-HT excitation was generally nonsensitive to rimonabant. The TRPV1 antagonist capsazepine reversed the decline in 5-HT excitation induced by high WIN55,2212-2 doses. Interestingly, TRPV1 is expressed in both DR and PFC (Liapi and Wood, 2005) and is implicated in anxiety, conditioned fear, and hippocampal long-term potentiation (Marsch et al., 2007) and in schizophrenia (Chahl, 2007), whose negative symptoms overlap with depression. Second, we consider the possible role of the putative CB3R or a non-CB1 cannabinoid receptor possessing a lower affinity to WIN55,212-2 proposed to be present in glutamatergic terminals and thus in a position to inhibit the release of excitatory amino acids (Hajos and Freund, 2002). Indeed, a reduction of evoked glutamate-mediated synaptic currents in 5-HT neurons was observed in acute DR slice preparations (Haj-Dahmane and Shen, 2005). Third, CB1R agonists may differentially act on GABAergic and glutamatergic pathways as observed in the ventral tegmental area (VTA) (Melis et al., 2004; Riegel and Lupica, 2004). Interestingly, a dual receptor mechanism was also reported to occur in the amygdala (Pistis et al., 2004), periaqueductal gray (Maione et al., 2006), and hippocampus (Hajos and Freund, 2002).

Altogether, these data are highly suggestive of a significant role of the mPFCv in mood control and in DR 5-HT activity through CB1R. We cannot, however, completely rule out the contributions of other brain regions and neurotransmitter systems that can act in concert with the mPFCv. The observed difference between systemic and intra-mPFCv WIN55,212-2 on the magnitude of FST effects may reflect extra-mPFCv contributions. CB1R agonists also modulate neuronal activity in various subcortical structures, e.g., the VTA (Diana et al., 1998), amygdala (Pistis et al., 2004), and locus ceruleus (Muntoni et al., 2006), all known to send afferents to the DR. Additional studies are underway to evaluate the influences of these areas on the activation of DR by cannabinoids.

Finally, this study confirms the emerging concept that the CB1R is an important new target in the development of antidepressant drugs. However, the challenge in the discovery of novel cannabinoid-derived agents lies in the development of agonists with selective antidepressant properties, and that minimize the unwanted psychotropic effects of cannabis.

Source, Graphs and Figures: Cannabinoids Elicit Antidepressant-Like Behavior and Activate Serotonergic Neurons through the Medial Prefrontal Cortex